In low grade glioma and subsets of IDH-mutant AML cases in which the presence of 2HG leads to a more benign outcome, we suggest that 2HG contributes to cancer initiation via inhibiting TET2, but suppresses cancer progression/proliferation via inhibiting FTO/MYC signaling.69 Here, TET2 is linked to cancer.